重磅利好！医保商保双驱动，创新药“黄金时代”来临！恒生医疗ETF(513060)大涨近2%

Group 1: Market Performance - The Hang Seng Medical ETF (513060) opened high and experienced a nearly 2% increase during the session, with a trading volume close to 1.8 billion and a turnover rate exceeding 20%, indicating active trading [1] - More than half of the constituent stocks rose, with notable increases such as Ascentage Pharma-B up over 6%, and other companies like Innovent Biologics and WuXi AppTec also showing significant gains [1] Group 2: Policy Impact - The National Healthcare Security Administration recently issued guidelines for the adjustment of the basic medical insurance directory and the commercial insurance innovative drug directory, marking a significant step for commercial health insurance in the multi-level medical security system [1][2] - The inclusion of the commercial health insurance innovative drug directory is expected to enhance the role of commercial insurance in the multi-level medical security system, providing more opportunities for the industry [1][2] Group 3: Innovation Drug Development - From 2018 to 2024, the number of Class 1 innovative drugs approved in China has shown a significant upward trend, with 48 drugs expected to be approved in 2024, more than five times that of 2018 [2] - The introduction of measures to support innovative drug development aims to guide the biopharmaceutical industry and avoid excessive competition, promoting high-quality development of innovative drugs [2][3] Group 4: Payment and Application Mechanisms - The establishment of a "commercial health insurance innovative drug directory" is expected to create a tiered security mechanism that promotes the global market development of innovative drugs [3] - Specific measures include optimizing the drug listing process and encouraging the use of innovative drugs in designated medical institutions, which will enhance the efficiency of the entire process [6][7] Group 5: Investment Opportunities - The Hang Seng Medical ETF is positioned as a core vehicle for investing in the turning point of innovative drugs, benefiting from policy support and historical valuation gaps [8] - The ETF's underlying assets include leading companies that are expected to benefit from payment reforms and the commercial insurance directory, indicating a potential for cash flow stability and valuation recovery [8]